Form 4: Corvus CFO Leiv Lea Granted 400,000 Stock Options

Corvus Pharmaceuticals' Chief Financial Officer, Leiv Lea, was granted 400,000 stock options with an exercise price of $8.81, vesting monthly over three years.

Summary

• Leiv Lea, Chief Financial Officer of Corvus Pharmaceuticals, Inc. (CRVS), was granted 400,000 stock options.
• The transaction date for this grant was December 4, 2025.
• Each option has an exercise price of $8.81.
• The options will vest as to 1/36th of the shares in successive, equal monthly installments starting from December 4, 2025, over a three-year period, subject to continued service.
• The options have an expiration date of December 4, 2035.
• Following this transaction, Leiv Lea beneficially owns 400,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for management alignment and retention, though it introduces potential future dilution. It's a standard compensation practice.

Positives

• The grant of 400,000 stock options to the Chief Financial Officer aligns management's interests with shareholder value creation.
• The vesting schedule over three years encourages long-term commitment and performance from the CFO.

Negatives

• The grant of stock options could lead to potential future dilution for existing shareholders if exercised.

Risks

• Potential future dilution of existing shareholders upon the exercise of the 400,000 stock options.

Future Outlook

The options will vest monthly over a three-year period starting December 4, 2025, contingent on the CFO's continued service, indicating a planned long-term incentive structure.

Industry Context

Executive stock option grants are a common practice in the biotechnology and pharmaceutical industry, like Corvus Pharmaceuticals, to attract, retain, and incentivize key management personnel. These grants typically align executive performance with long-term company growth and shareholder returns, especially in sectors with long development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of 400,000 stock options to a Chief Financial Officer is a standard form of executive compensation in the biotech industry, comparable to practices at similar-sized pharmaceutical companies.
• A three-year monthly vesting schedule is typical for executive equity awards, designed to promote long-term retention and performance, aligning with industry benchmarks for executive incentive plans.
• The exercise price being the market price on the grant date (implied, as no other price is given) is also standard for incentive stock options.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from increased management alignment and motivation to improve company performance.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives.

Next Steps

• Continued vesting of the 400,000 stock options in monthly installments over the next three years, subject to Leiv Lea's continued service.
• Potential exercise of vested options by Leiv Lea at or before the expiration date of December 4, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a key executive, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Corvus Pharmaceuticals, nor does it provide new insights into the company's operational or financial performance. Therefore, a "hold" recommendation is appropriate as this event alone is unlikely to drive significant stock price movement or warrant a change in an existing investment position.

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Executive Compensation, CFO, Leiv Lea, SEC Form 4, Beneficial Ownership, Equity Grant